Incyte Corporation (INCY)
| Market Cap | 11.49B |
| Revenue (ttm) | 3.70B |
| Net Income (ttm) | 597.60M |
| Shares Out | 224.53M |
| EPS (ttm) | 2.65 |
| PE Ratio | 19.31 |
| Forward PE | 11.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,751,061 |
| Open | 51.65 |
| Previous Close | 51.74 |
| Day's Range | 50.35 - 51.85 |
| 52-Week Range | 50.27 - 75.74 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 74.69 (+45.94%) |
| Earnings Date | Apr 30, 2024 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]
Financial Performance
In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $74.69, which is an increase of 45.94% from the latest price.
News
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202...
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)---- $INCY--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that ...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa.
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative ne...
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ax...
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference.
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities.
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®).
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2023 Financial Results.
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference.
Incyte Stock Is the S&P 500's Top Performer. Here's Why It's Surging.
Shares of the biopharmaceutical company are on pace for their best day in more than six years.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Uns...
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)---- $INCY--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in C...
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting.
Drugmaker Incyte's quarterly profit beats on lower costs
Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.